Next Article in Journal
From Gene- and Protein Expression Patterns to Biological Mechanisms: -omics in Pharmacology and Toxicology
Previous Article in Journal
Targeting Proteinkinases: The Selectivity Problem
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessAbstract
Sci. Pharm. 2009, 77(Plenary Lectures (PL)), 166; (registering DOI)

Nanotechnologies for the Delivery of Nucleic Acids and Contrast Agents

UMR CNRS 8612, University of Paris Sud 11, Châtenay-Malabry, France
Received: 16 April 2009 / Accepted: 16 April 2009 / Published: 16 April 2009
PDF [194 KB, uploaded 11 May 2017]


Strategies for inhibiting gene expression have been applied in several therapeutic applications Indeed, administration of nucleic acids such as antisense oligonucleotides (AS-ODNs) or small interfering RNA (siRNA) has raised a lot of interests in the recent years for the treatment of several diseases. Among the promising therapeutic approaches is antisense technology – oligonucleotides that are designed to be complementary to a target RNA sequence so they can bind to the target and stop the production of undesirable proteins. A more recent approach for targeting mRNA is the use of siRNA which can lead to hydrolysis of the target mRNA homologous at the site where the antisense strand of the siRNA is bound. Very similarly DNA delivery aiming to express intracellularly a protein that is absent or deficient raises close issues to AS-ODNs or siRNAs with the exception that the intracellular target is the nucleus, meaning one more barrier to cross. Nucleic acids are characterized by a high molecular weight and a negative charge being not able to pass biological membranes. Out of these reasons, two strategies are possible to improve their delivery: The first is to develop chemical modified nucleic acids in order to protect them or/and to improve their cellular uptake. The second strategy comprises the development of particulate carriers for oligonucleotides delivery which increase tremendously the efficacy of all these molecules.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

FATTAL, E. Nanotechnologies for the Delivery of Nucleic Acids and Contrast Agents. Sci. Pharm. 2009, 77, 166.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top